Cancer-related cognitive impairment impacts patient functioning across various oncology indications. An estimated 75% of all oncology patients experience changes in memory, executive function, attention, and processing speed during treatment.
Cogstate helps sponsors better evaluate cognitive impairment throughout the development lifecycle of new therapeutics in both adult and pediatric populations. We do this by providing sensitive and reliable computerized cognitive testing, alongside patient reported outcomes in collaboration with our leading eCOA vendor partners.
Download the fact sheet below to learn more about how we support oncology clinical trials globally.